Colorectal Cancer | Specialty

Optimizing Treatment With Regorafenib in mCRC

July 23rd 2014

BRAF-Mutated Colorectal Cancer

July 23rd 2014

Second-Line Treatment Options in mCRC

July 23rd 2014

Future Analyses From the 80405 mCRC Trial

July 23rd 2014

Conducting Extended RAS Testing in CRC

July 23rd 2014

Extended RAS Testing in Metastatic CRC

July 23rd 2014

CALGB 80405 Trial Results in mCRC

July 23rd 2014

Introduction: Bevacizumab Versus Cetuximab in mCRC

July 23rd 2014

Dr. Hoff on Delivering Chemotherapy Until Progression Versus Complete Stop in mCRC

July 22nd 2014

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses a meta-analysis of randomized trials that examined the effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer (mCRC).

Dr. Fakih on Advances in Liver-Directed Therapies in CRC

July 3rd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses recent advances in liver-directed therapies in colorectal cancer (CRC).

Dr. Arnold on a Phase III Trial Examining Options for Maintenance Therapy in mCRC

July 2nd 2014

Dirk Arnold, MD, director, Department of Medical Oncology, Tumour Biology Centre, Freiburg, Germany, discusses a phase III trial looking at options for maintenance therapy for metastatic colorectal cancer (mCRC).

Dr. Yoshino Discusses the Safety Profile of TAS-102

June 30th 2014

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Cetuximab, Bevacizumab Equivalent as First-Line Therapy in KRAS Wild-Type mCRC

June 28th 2014

A head-to-head comparison of cetuximab and bevacizumab in a phase III trial that was nearly 10 years in the making showed equivalence for chemotherapy plus either agent in terms of OS, PFS, and response rates for patients with certain previously untreated metastatic colorectal cancers.

Palliative Resection Associated With Improved Survival in mCRC

June 28th 2014

Initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit compared with the same treatments administered in the reverse order in patients with mCRC receiving palliative care.

Dr. Venook Discusses Implications of the 80405 Study

June 28th 2014

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer.

TAS-102 Monotherapy Improves OS, PFS in Refractory mCRC

June 28th 2014

Treatment with the oral nucleoside TAS-102 significantly extended OS and PFS for patients with metastatic colorectal cancer refractory to standard therapies.

Active Maintenance Improves PFS in mCRC

June 28th 2014

Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer.

Regorafenib Offers Effective Option for Asian Patients With mCRC

June 27th 2014

Treatment with regorafenib significantly improved OS and PFS in an Asian population of patients with previously treated mCRC.

Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC

June 27th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

Dr. Tabernero on Sequencing Angiogenesis Inhibitors in mCRC

June 27th 2014

Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.